Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2001

View Archived Issues

SBIR grant awarded to Antigen Express for development of prostate cancer cell vaccine

Alizyme makes significant progress across product development portfolio during 2000

Adolor advances lead product into phase III trials during 2000

Study demonstrates Origenix compounds effective against HBV replication

OBJECT trial results reported to favor Ditropan XL over Detrol

Cubist achieves milestone for Cidecin, triggering payment from Gilead

ConjuChem's CJC-1008 demonstrates positive phase I results

Oral formulation of Isis antisense drug enters clinical evaluation

Abbott presents new antimitotic sulfonates and prodrugs with improved PK profile at ACS meeting

Noninvasive lung cancer diagnostic launched in E.U.

Cyclotriphosphazene-platinum(II) conjugate selected by Korean researchers as clinical candidate

Natrecor scheduled for FDA advisory committee review

SPC-8490, a third-generation SERM active against gynecological tumors, devoid of uterine stimulation

Orion's Simdax receives favorable opinion in several E.U. countries

Panacos and the NCI begin joint HIV drug discovery program

Nonbenzamidine factor Xa inhibitors from DuPont with excellent in vitro profile and improved PK

Pyridine-based inhibitors of cell cycle kinases in the AstraZeneca pipeline

Chemokine receptor modulators and their use in therapy reported by AstraZeneca

Novel series of broad-spectrum antibacterial agents claimed in recent patent

U.S. patent covers altered peptide ligands, including NBI-6024, and use in diabetes Rx

Schering AG presents new NOS inhibitors

Naturally produced antibiotics especially active against mycobacteria, according to MCRF

Quinoline derivatives synthesized at Nippon Soda are potent and selective PDE5 inhibitors

Aminothiazole CDK2 inhibitors undergo preclinical testing at BMS

Phytopharm's P-57 well tolerated in first stage of proof-of-principle trial

First patient treated in phase I study of Alzheimer's disease gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...